{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T21:20:44Z","timestamp":1788384044416,"version":"build-2803163510"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s00059-022-05138-2","type":"journal-article","created":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T13:11:27Z","timestamp":1662988287000},"page":"401-409","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Cardiorenal benefits of mineralocorticoid antagonists in CKD and type\u00a02 diabetes","Kardiorenaler Nutzen von Mineralokortikoidrezeptorantagonisten bei chronischer Nierenerkrankung und Typ-2-Diabetes"],"prefix":"10.1007","volume":"47","author":[{"given":"Hermann","family":"Haller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,12]]},"reference":[{"key":"5138_CR1","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1093\/ndt\/gfz174","volume":"34","author":"KJ Jager","year":"2019","unstructured":"Jager\u00a0KJ, Kovesdy\u00a0C, Langham\u00a0R et al (2019) A single number for advocacy and communication-worldwide more than 850\u00a0million individuals have kidney diseases. Nephrol Dial Transplant 34:1803\u20131805","journal-title":"Nephrol Dial Transplant"},{"key":"5138_CR2","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.2215\/CJN.11491116","volume":"12","author":"RZ Alicic","year":"2017","unstructured":"Alicic\u00a0RZ, Rooney\u00a0MT, Tuttle\u00a0KR (2017) Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol 12:2032\u20132045","journal-title":"Clin J Am Soc Nephrol"},{"key":"5138_CR3","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner\u00a0BM, Cooper\u00a0ME, de Zeeuw\u00a0D et\u00a0al (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N\u00a0Engl J Med 345:861\u2013869","journal-title":"N Engl J Med"},{"key":"5138_CR4","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis\u00a0EJ, Hunsicker\u00a0LG, Clarke\u00a0WR et al (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N\u00a0Engl J Med 345:851\u2013860","journal-title":"N Engl J Med"},{"key":"5138_CR5","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1093\/ndt\/gfy407","volume":"34","author":"P Sarafidis","year":"2019","unstructured":"Sarafidis\u00a0P, Ferro\u00a0CJ, Morales\u00a0E et al (2019) SGLT\u20112 inhibitors and GLP\u20111 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA\u2011m and the DIABESITY working groups of the ERA-EDTA. Nephrol Dial Transplant 34:208\u2013230","journal-title":"Nephrol Dial Transplant"},{"key":"5138_CR6","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic\u00a0V, Jardine\u00a0MJ, Neal\u00a0B et\u00a0al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N\u00a0Engl J Med 380:2295\u20132306","journal-title":"N Engl J Med"},{"key":"5138_CR7","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/sj.ki.5000058","volume":"69","author":"BO Eriksen","year":"2006","unstructured":"Eriksen\u00a0BO, Ingebretsen\u00a0OC (2006) The progression of chronic kidney disease: a\u00a010-year population-based study of the effects of gender and age. Kidney Int 69:375\u2013382","journal-title":"Kidney Int"},{"key":"5138_CR8","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1113\/jphysiol.2014.272328","volume":"592","author":"C Mora-Fern\u00e1ndez","year":"2014","unstructured":"Mora-Fern\u00e1ndez\u00a0C, Dom\u00ednguez-Pimentel\u00a0V, de Fuentes\u00a0MM et al (2014) Diabetic kidney disease: from physiology to therapeutics. J\u00a0Physiol 592:3997\u20134012","journal-title":"J Physiol"},{"key":"5138_CR9","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1159\/000499486","volume":"143","author":"A Chagnac","year":"2019","unstructured":"Chagnac\u00a0A, Zingerman\u00a0B, Rozen-Zvi\u00a0B, Herman-Edelstein\u00a0M (2019) Consequences of glomerular hyperfiltration: the role of physical forces in the pathogenesis of chronic kidney disease in diabetes and obesity. Nephron 143:38\u201342","journal-title":"Nephron"},{"key":"5138_CR10","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1111\/j.1523-1755.2005.09911.x","volume":"68","author":"G Remuzzi","year":"2005","unstructured":"Remuzzi\u00a0G, Perico\u00a0N, Macia\u00a0M, Ruggenenti\u00a0P (2005) The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int Suppl 68:S57\u2013S65","journal-title":"Kidney Int Suppl"},{"key":"5138_CR11","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/jvim.15454","volume":"33","author":"MK Ames","year":"2019","unstructured":"Ames\u00a0MK, Atkins\u00a0CE, Pitt\u00a0B (2019) The renin-angiotensin-aldosterone system and its suppression. J\u00a0Vet Intern Med 33:363\u2013382","journal-title":"J Vet Intern Med"},{"key":"5138_CR12","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.mce.2011.07.034","volume":"350","author":"NG Hattangady","year":"2012","unstructured":"Hattangady\u00a0NG, Olala\u00a0LO, Bollag\u00a0WB, Rainey\u00a0WE (2012) Acute and chronic regulation of aldosterone production. Mol Cell Endocrinol 350:151\u2013162","journal-title":"Mol Cell Endocrinol"},{"key":"5138_CR13","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1053\/j.ackd.2017.12.002","volume":"25","author":"RZ Alicic","year":"2018","unstructured":"Alicic\u00a0RZ, Johnson\u00a0EJ, Tuttle\u00a0KR (2018) Inflammatory mechanisms as new biomarkers and therapeutic targets for diabetic kidney disease. Adv Chronic Kidney Dis 25:181\u2013191","journal-title":"Adv Chronic Kidney Dis"},{"key":"5138_CR14","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/s41584-019-0322-7","volume":"15","author":"JHW Distler","year":"2019","unstructured":"Distler\u00a0JHW, Gy\u00f6rfi\u00a0AH, Ramanujam\u00a0M et\u00a0al (2019) Shared and distinct mechanisms of fibrosis. Nat Rev Rheumatol 15:705\u2013730","journal-title":"Nat Rev Rheumatol"},{"key":"5138_CR15","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1093\/ckj\/sfw096","volume":"9","author":"R Guiteras","year":"2016","unstructured":"Guiteras\u00a0R, Flaquer\u00a0M, Cruzado\u00a0JM (2016) Macrophage in chronic kidney disease. Clin Kidney\u00a0J 9:765\u2013771","journal-title":"Clin Kidney J"},{"key":"5138_CR16","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1369\/0022155419852932","volume":"67","author":"LM Black","year":"2019","unstructured":"Black\u00a0LM, Lever\u00a0JM, Agarwal\u00a0A (2019) Renal inflammation and fibrosis: a double-edged sword. J\u00a0Histochem Cytochem 67:663\u2013681","journal-title":"J Histochem Cytochem"},{"key":"5138_CR17","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1046\/j.1523-1755.2000.00311.x","volume":"58","author":"T Wada","year":"2000","unstructured":"Wada\u00a0T, Furuichi\u00a0K, Sakai\u00a0N et al (2000) Up-regulation of monocyte chemoattractant protein\u20111 in tubulointerstitial lesions of human diabetic nephropathy. Kidney Int 58:1492\u20131499","journal-title":"Kidney Int"},{"key":"5138_CR18","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1161\/01.HYP.0000193502.77417.17","volume":"46","author":"PJ Fuller","year":"2005","unstructured":"Fuller\u00a0PJ, Young\u00a0MJ (2005) Mechanisms of mineralocorticoid action. Hypertension 46:1227\u20131235","journal-title":"Hypertension"},{"key":"5138_CR19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1530\/JOE-11-0372","volume":"213","author":"PJ Fuller","year":"2012","unstructured":"Fuller\u00a0PJ, Yao\u00a0Y, Yang\u00a0J, Young\u00a0MJ (2012) Mechanisms of ligand specificity of the mineralocorticoid receptor. J\u00a0Endocrinol 213:15\u201324","journal-title":"J Endocrinol"},{"issue":"2","key":"5138_CR20","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1161\/01.CIR.92.2.175","volume":"92","author":"M Lombes","year":"1995","unstructured":"Lombes\u00a0M, Alfaidy\u00a0N, Eugene\u00a0E, Lessana\u00a0A, Farman\u00a0N, Bonvalet\u00a0J\u2011P (1995) Prerequisite for cardiac aldosterone action: mineralocorticoid receptor and 11\u03b2-hydroxysteroid dehydrogenase in the human heart. Circulation 92(2):175\u2013182","journal-title":"Circulation"},{"key":"5138_CR21","doi-asserted-by":"publisher","first-page":"e012","DOI":"10.1621\/nrs.05012","volume":"5","author":"S Viengchareun","year":"2007","unstructured":"Viengchareun\u00a0S, Le Menuet\u00a0D, Martinerie\u00a0L, Munier\u00a0M, Pascual-Le Tallec\u00a0L, Lomb\u00e8s\u00a0M (2007) The mineralocorticoid receptor: insights into its molecular and (patho)physiological biology. Nucl Recept Signal 5:e12","journal-title":"Nucl Recept Signal"},{"key":"5138_CR22","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1146\/annurev.pharmtox.010909.105610","volume":"50","author":"M Bader","year":"2010","unstructured":"Bader\u00a0M (2010) Tissue renin-angiotensin-aldosterone systems: targets for pharmacological therapy. Annu Rev Pharmacol Toxicol 50:439\u2013465","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"5138_CR23","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.freeradbiomed.2012.05.011","volume":"53","author":"N Queisser","year":"2012","unstructured":"Queisser\u00a0N, Schupp\u00a0N (2012) Aldosterone, oxidative stress, and NF-\u03baB activation in hypertension-related cardiovascular and renal diseases. Free Radic Biol Med 53:314\u2013327","journal-title":"Free Radic Biol Med"},{"key":"5138_CR24","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1096\/fj.05-4642fje","volume":"20","author":"S Johar","year":"2006","unstructured":"Johar\u00a0S, Cave\u00a0AC, Narayanapanicker\u00a0A, Grieve\u00a0DJ, Shah\u00a0AM (2006) Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a\u00a0Nox2-containing NADPH oxidase. FASEB\u00a0J 20:1546\u20131548","journal-title":"FASEB J"},{"issue":"2","key":"5138_CR25","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1161\/HYPERTENSIONAHA.107.109645","volume":"52","author":"L Michea","year":"2008","unstructured":"Michea\u00a0L, Villagr\u00e1n\u00a0A, Urz\u00faa\u00a0A, Kuntsmann\u00a0S, Venegas\u00a0P, Carrasco\u00a0L, Gonzalez\u00a0M, Marusic\u00a0ET (2008) Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and prevents oxidative stress in uremic rats. Hypertension 52(2):295\u2013300","journal-title":"Hypertension"},{"key":"5138_CR26","doi-asserted-by":"publisher","first-page":"3579","DOI":"10.2174\/13816128113196660748","volume":"20","author":"S Karbach","year":"2014","unstructured":"Karbach\u00a0S, Wenzel\u00a0P, Waisman\u00a0A, Munzel\u00a0T, Daiber\u00a0A (2014) eNOS uncoupling in cardiovascular diseases--the role of oxidative stress and inflammation. Curr Pharm Des 20:3579\u20133594","journal-title":"Curr Pharm Des"},{"key":"5138_CR27","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.steroids.2014.04.005","volume":"91","author":"NC Bene","year":"2014","unstructured":"Bene\u00a0NC, Alcaide\u00a0P, Wortis\u00a0HH, Jaffe\u00a0IZ (2014) Mineralocorticoid receptors in immune cells: emerging role in cardiovascular disease. Steroids 91:38\u201345","journal-title":"Steroids"},{"key":"5138_CR28","first-page":"829786","volume":"2012","author":"DA Kasal","year":"2012","unstructured":"Kasal\u00a0DA, Schiffrin\u00a0EL (2012) Angiotensin II, aldosterone, and anti-inflammatory lymphocytes: interplay and therapeutic opportunities. Int J Hypertens 2012:829786","journal-title":"Int J Hypertens"},{"key":"5138_CR29","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1161\/HYPERTENSIONAHA.113.01803","volume":"63","author":"AJ Rickard","year":"2014","unstructured":"Rickard\u00a0AJ, Morgan\u00a0J, Chrissobolis\u00a0S, Miller\u00a0AA, Sobey\u00a0CG, Young\u00a0MJ (2014) Endothelial cell mineralocorticoid receptors regulate DOC\/salt-mediated cardiac remodeling and vascular reactivity, but not blood pressure. Hypertension 63:1033\u20131040","journal-title":"Hypertension"},{"key":"5138_CR30","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.exer.2011.12.012","volume":"96","author":"Y Liu","year":"2012","unstructured":"Liu\u00a0Y, Hirooka\u00a0K, Nishiyama\u00a0A, Lei\u00a0B, Nakamura\u00a0T, Itano\u00a0T, Fujita\u00a0T, Zhang\u00a0J, Shiraga\u00a0F (2012) Activation of the aldosterone\/mineralocorticoid receptor system and protective effects of mineralocorticoid receptor antagonism in retinal ischemia-reperfusion injury. Exp Eye Res 96:116\u2013123","journal-title":"Exp Eye Res"},{"key":"5138_CR31","doi-asserted-by":"publisher","first-page":"3350","DOI":"10.1172\/JCI41080","volume":"120","author":"MG Usher","year":"2010","unstructured":"Usher\u00a0MG, Duan\u00a0SZ, Ivaschenko\u00a0CY, Frieler\u00a0RA, Berger\u00a0S, Sch\u00fctz\u00a0G, Lumeng\u00a0CN, Mortensen\u00a0RM (2010) Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J\u00a0Clin Invest 120:3350\u20133364","journal-title":"J Clin Invest"},{"key":"5138_CR32","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1161\/HYPERTENSIONAHA.111.181123","volume":"59","author":"DA Kasal","year":"2012","unstructured":"Kasal\u00a0DA, Barhoumi\u00a0T, Li\u00a0MW, Yamamoto\u00a0N, Zdanovich\u00a0E, Rehman\u00a0A, Neves\u00a0MF, Laurant\u00a0P, Paradis\u00a0P, Schiffrin\u00a0EL (2012) T regulatory lymphocytes prevent aldosterone-induced vascular injury. Hypertension 59:324\u2013330","journal-title":"Hypertension"},{"key":"5138_CR33","doi-asserted-by":"publisher","first-page":"191","DOI":"10.4049\/jimmunol.0802886","volume":"184","author":"AA Herrada","year":"2010","unstructured":"Herrada\u00a0AA, Contreras\u00a0FJ, Marini\u00a0NP, Amador\u00a0CA, Gonz\u00e1lez\u00a0PA, Cort\u00e9s\u00a0CM, Riedel\u00a0CA, Carvajal\u00a0CA, Figueroa\u00a0F, Michea\u00a0LF et al (2010) Aldosterone promotes autoimmune damage by enhancing Th17-mediated immunity. J\u00a0Immunol 184:191\u2013202","journal-title":"J Immunol"},{"key":"5138_CR34","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1161\/CIRCULATIONAHA.107.748640","volume":"117","author":"C Guo","year":"2008","unstructured":"Guo\u00a0C, Ricchiuti\u00a0V, Lian\u00a0BQ, Yao\u00a0TM, Coutinho\u00a0P, Romero\u00a0JR, Li\u00a0J, Williams\u00a0GH, Adler\u00a0GK (2008) Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation 117:2253\u20132261","journal-title":"Circulation"},{"key":"5138_CR35","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1681\/ASN.2014010117","volume":"25","author":"HJ Anders","year":"2014","unstructured":"Anders\u00a0HJ, Schaefer\u00a0L (2014) Beyond tissue injury-damage-associated molecular patterns, toll-like receptors, and inflammasomes also drive regeneration and fibrosis. J\u00a0Am Soc Nephrol 25:1387\u20131400","journal-title":"J Am Soc Nephrol"},{"key":"5138_CR36","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1053\/j.ajkd.2007.10.040","volume":"51","author":"AS Bomback","year":"2008","unstructured":"Bomback\u00a0AS, Kshirsagar\u00a0AV, Amamoo\u00a0MA, Klemmer\u00a0PJ (2008) Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a\u00a0systematic review. Am J Kidney Dis 51:199\u2013211","journal-title":"Am J Kidney Dis"},{"key":"5138_CR37","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1056\/NEJM200109203451215","volume":"345","author":"A Chrysostomou","year":"2001","unstructured":"Chrysostomou\u00a0A, Becker\u00a0G (2001) Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N\u00a0Engl J Med 345:925\u2013926","journal-title":"N Engl J Med"},{"key":"5138_CR38","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1161\/01.HYP.0000044937.95080.E9","volume":"41","author":"A Sato","year":"2003","unstructured":"Sato\u00a0A, Hayashi\u00a0K, Naruse\u00a0M, Saruta\u00a0T (2003) Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 41:64\u201368","journal-title":"Hypertension"},{"key":"5138_CR39","doi-asserted-by":"publisher","first-page":"940","DOI":"10.2215\/CJN.00240106","volume":"1","author":"M Epstein","year":"2006","unstructured":"Epstein\u00a0M, Williams\u00a0GH, Weinberger\u00a0M et\u00a0al (2006) Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 1:940\u2013951","journal-title":"Clin J Am Soc Nephrol"},{"key":"5138_CR40","first-page":"CD007004","volume":"4","author":"D Bolignano","year":"2014","unstructured":"Bolignano\u00a0D, Palmer\u00a0SC, Navaneethan\u00a0SD, Strippoli\u00a0GF (2014) Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev 4:CD7004","journal-title":"Cochrane Database Syst Rev"},{"key":"5138_CR41","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1053\/j.ackd.2014.08.003","volume":"22","author":"MH Schwenk","year":"2015","unstructured":"Schwenk\u00a0MH, Hirsch\u00a0JS, Bomback\u00a0AS (2015) Aldosterone blockade in CKD: emphasis on pharmacology. Adv Chronic Kidney Dis 22:123\u2013132","journal-title":"Adv Chronic Kidney Dis"},{"key":"5138_CR42","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.mce.2011.06.025","volume":"350","author":"P Kolkhof","year":"2012","unstructured":"Kolkhof\u00a0P, Borden\u00a0SA (2012) Molecular pharmacology of the mineralocorticoid receptor: Prospects for novel therapeutics. Mol Cell Endocrinol 350:310\u2013317","journal-title":"Mol Cell Endocrinol"},{"key":"5138_CR43","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.mce.2011.07.019","volume":"350","author":"R Dooley","year":"2012","unstructured":"Dooley\u00a0R, Harvey\u00a0BJ, Thomas\u00a0W (2012) Non-genomic actions of aldosterone: from receptors and signals to membrane targets. Mol Cell Endocrinol 350:223\u2013234","journal-title":"Mol Cell Endocrinol"},{"key":"5138_CR44","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1161\/CIRCULATIONAHA.108.809194","volume":"119","author":"W Iraqi","year":"2009","unstructured":"Iraqi\u00a0W, Rossignol\u00a0P, Angioi\u00a0M, Fay\u00a0R, Nu\u00e9e\u00a0J, Ketelslegers\u00a0JM, Vincent\u00a0J, Pitt\u00a0B, Zannad\u00a0F (2009) Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. Circulation 119:2471\u20132479","journal-title":"Circulation"},{"issue":"9","key":"5138_CR45","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.metabol.2016.06.001","volume":"65","author":"P Yang","year":"2016","unstructured":"Yang\u00a0P, Huang\u00a0T, Xu\u00a0G (2016) The novel mineralocorticoid receptor antagonist finerenone in diabetic kidney disease: progress and challenges. Metabolism 65(9):1342\u20131349","journal-title":"Metabolism"},{"key":"5138_CR46","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/ki.2012.352","volume":"83","author":"J Barrera-Chimal","year":"2013","unstructured":"Barrera-Chimal\u00a0J, P\u00e9rez-Villalva\u00a0R, Rodr\u00edguez-Romo\u00a0R, Reyna\u00a0J, Uribe\u00a0N, Gamba\u00a0G, Bobadilla\u00a0NA (2013) Spironolactone prevents chronic kidney disease caused by ischemic acute kidney injury. Kidney Int 83:93\u2013103","journal-title":"Kidney Int"},{"key":"5138_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007004","author":"SD Navaneethan","year":"2009","unstructured":"Navaneethan\u00a0SD, Nigwekar\u00a0SU, Sehgal\u00a0AR, Strippoli\u00a0GF (2009) Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD007004","journal-title":"Cochrane Database Syst Rev"},{"issue":"36","key":"5138_CR48","doi-asserted-by":"publisher","first-page":"21876","DOI":"10.1074\/jbc.M115.657957","volume":"290","author":"L Amazit","year":"2015","unstructured":"Amazit\u00a0L, Le Billan\u00a0F, Kolkhof\u00a0P, Lamribet\u00a0K, Viengchareun\u00a0S, Fay\u00a0MR, Khan\u00a0JA, Hillisch\u00a0A, Lomb\u00e8s\u00a0M, Rafestin-Oblin\u00a0ME, Fagart\u00a0J (2015) Finerenone impedes aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor Coactivator\u20111. J\u00a0Biol Chem 290(36):21876\u201321889","journal-title":"J Biol Chem"},{"key":"5138_CR49","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1159\/000371497","volume":"40","author":"LM Ruilope","year":"2014","unstructured":"Ruilope\u00a0LM, Agarwal\u00a0R, Chan\u00a0JC, Cooper\u00a0ME, Gansevoort\u00a0RT, Haller\u00a0H, Remuzzi\u00a0G, Rossing\u00a0P, Schmieder\u00a0RE, Nowack\u00a0C (2014) Rationale, design, and baseline characteristics of ARTS-DN: a\u00a0randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a\u00a0clinical diagnosis of diabetic nephropathy. Am J Nephrol 40:572\u2013581","journal-title":"Am J Nephrol"},{"key":"5138_CR50","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1001\/jama.2015.10081","volume":"314","author":"GL Bakris","year":"2015","unstructured":"Bakris\u00a0GL, Agarwal\u00a0R, Chan\u00a0JC, Cooper\u00a0ME, Gansevoort\u00a0RT, Haller\u00a0H, Remuzzi\u00a0G, Rossing\u00a0P, Schmieder\u00a0RE, Nowack\u00a0C, Mineralocorticoid Receptor Antagonist Tolerability Study\u2013Diabetic Nephropathy (ARTS-DN) Study Group (2015) Effect of finerenone on albuminuria in patients with diabetic nephropathy: a\u00a0randomized clinical trial. JAMA 314:884\u2013894","journal-title":"JAMA"},{"key":"5138_CR51","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris\u00a0GL, Agarwal\u00a0R, Anker\u00a0SD et\u00a0al (2020) Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N\u00a0Engl J Med 383:2219\u20132229","journal-title":"N Engl J Med"},{"key":"5138_CR52","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt\u00a0B, Filippatos\u00a0G, Agarwal\u00a0R et\u00a0al (2021) Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N\u00a0Engl J Med 385:2252\u20132263","journal-title":"N Engl J Med"},{"key":"5138_CR53","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1159\/000503712","volume":"50","author":"LM Ruilope","year":"2019","unstructured":"Ruilope\u00a0LM, Agarwal\u00a0R, Anker\u00a0SD et\u00a0al (2019) Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial. Am J Nephrol 50:345\u2013356","journal-title":"Am J Nephrol"},{"issue":"6","key":"5138_CR54","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal\u00a0R, Filippatos\u00a0G, Pitt\u00a0B, Anker\u00a0SD, Rossing\u00a0P, Joseph\u00a0A, Kolkhof\u00a0P, Nowack\u00a0C, Gebel\u00a0M, Ruilope\u00a0LM, Bakris\u00a0GL, FIDELIO-DKD and FIGARO-DKD investigators (2022) Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart\u00a0J 43(6):474\u2013484","journal-title":"Eur Heart J"}],"container-title":["Herz"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-022-05138-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00059-022-05138-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-022-05138-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T15:05:46Z","timestamp":1664550346000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00059-022-05138-2"}},"subtitle":["Lessons from the FIGARO-DKD trial","Erfahrungen aus der FIGARO-CKD- und FIDELITY-Studie"],"short-title":[],"issued":{"date-parts":[[2022,9,12]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["5138"],"URL":"https:\/\/doi.org\/10.1007\/s00059-022-05138-2","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,12]]},"assertion":[{"value":"22 August 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"H.\u00a0Haller has received lecture fees from AstraZeneca, Bayer, Vifor, Otsuka, Glaxo and honoraria for consulting from AstraZeneca, Bayer, Vifor, Travere.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this article no studies with human participants or animals were performed by any of the authors. All studies mentioned were in accordance with the ethical standards indicated in each case.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}